Small‐vessel vasculitis following Oxford‐AstraZeneca vaccination against SARS‐CoV‐2

Guzmán‐Pérez, Luisa María; Puerta‐Peña, Mario; Falkenhain‐López, Daniel; Montero‐Menárguez, Julia; Gutiérrez‐Collar, Christian; Rodríguez‐Peralto, José Luis; Sanz-Bueno, Jimena

doi:10.1111/jdv.17547

Cited by 20 publications

(14 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only one had cryoglobulinemia. 7 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 36 , 37 Nastro et al 21 reported an 84‐year‐old woman, with history of chronic kidney disease and depressive disorder, developed burning pain on the distal part of right leg and foot, followed by ipsilateral multiple non‐confluent purpuric papules and vesicles few hours after she received the first dose of Pfizer‐BioNTech COVID‐19 vaccine. PCR of a skin swab for varicella‐zoster virus (VZV) resulted positive, and VZV IgM and IgG antibodies were positive.…”

Section: Resultsmentioning

confidence: 99%

SARS‐CoV‐2 vaccination‐induced cutaneous vasculitis: Report of two new cases and literature review

Abdelmaksoud

Wollina

Temiz

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

Currently the most powerful tool in combating the COVID‐19 pandemic is vaccination against SARS‐CoV‐2. A growing percentage of the world's population is being vaccinated. Various vaccines are worldwide on the market. Several adverse reactions have been reported as a part of post‐marketing surveillance of COVID‐19 vaccines. Among the possible adverse events, cutaneous vasculitis has occasionally been reported. We present a narrative review on cutaneous vasculitis related to COVID‐19‐vaccination to summarize clinical findings, histopathology, treatment and outcome. We searched for “COVID vaccine”, “COVID vaccination” AND “cutaneous vasculitis” in PUBMED. Articles in English have been selected, from inception to December 2021, and analyzed for patient's characteristics, type of vaccine, time of appearance of cutaneous vasculitis and clinico‐histopathologic type. Treatment and outcome have also been considered in this narrative review. Two new unpublished cases of ours were added. Cutaneous vasculitis is a rare adverse event to COVID‐19 vaccination. It has been observed with mRNA and adenovirus‐vector vaccines. IgA vasculitis, lymphocytic and ANCA‐associated vasculitis, leukocytoclastic and urticarial vasculitis have been reported. This adverse event can occur after first or second shot. Most cases run a mild to moderate course. Cornerstone of medical treatment are systemic corticosteroids. Complete remission could be achieved in most patients. Vasculitis may not be considered as a contraindication of vaccination, being uncommonly reported and shows a favorable prognosis. The benefit of the vaccination remains high especially for immunocompromised patients. COVID‐vaccine induced vasculitis is important in the differential diagnosis of purpuric and vasculitis disorders.

show abstract

Section: Resultsmentioning

confidence: 99%

SARS‐CoV‐2 vaccination‐induced cutaneous vasculitis: Report of two new cases and literature review

Abdelmaksoud

Wollina

Temiz

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“… 7 On the contrary, vasculitis was also reported after COVID‐19 vaccination. Several case reports were reported skin vasculitis following vector‐based vaccines including AZ 27 , 28 , 29 and Johnson Johnson. 30 …”

Section: Discussionmentioning

confidence: 99%

Serious events following COVID‐19 vaccination with ChAdOx1 nCoV‐19 vaccine (Vaxzevria): A short case series from Iran

Khajavirad

Salehi

Ghadery

et al. 2022

Clinical Case Reports

View full text Add to dashboard Cite

In 2020, the SARS‐COV‐2 disease (COVID‐19) imposed huge challenges on the health, economic, and political systems, and by the end of the year, hope had been born with the release of COVID‐19 vaccines aimed at bringing the pandemic to an end. However, the COVID‐19 vaccination programs have sparked several concerns and ongoing debates over safety issues. Here, we presented three cases of patients with serious adverse events, encephalopathy, vaccine‐induced thrombotic thrombocytopenia, and leukocytoclastic vasculitis, after receiving the ChAdOx1 nCoV‐19 vaccine. Therefore, it is critical to investigate and report the occurrence of adverse reactions following vaccination, particularly serious ones, as it contributes to the growing body of research and assists clinicians in better diagnosing and managing them.

show abstract

“…Injection‐site skin reaction has been reported as a common adverse drug reaction; however, there has been only one report of vasculitis so far with the ChAdOx1 nCoV‐19 vaccine. 1 Herein, we present a case of new‐onset leukocytoclastic vasculitis following ChAdOx1 nCoV‐19 vaccination.…”

Section: Figurementioning

confidence: 98%

Leukocytoclastic vasculitis after coronavirus disease 2019 vaccination

Jin

Ahn

Jang

et al. 2021

The Journal of Dermatology

View full text Add to dashboard Cite

Small‐vessel vasculitis following Oxford‐AstraZeneca vaccination against SARS‐CoV‐2

Abstract: mask induced acne) in health care professionals of tertiary care hospitals of Lahore during COVID-19 Pandemic.

Cited by 20 publications

References 7 publications

SARS‐CoV‐2 vaccination‐induced cutaneous vasculitis: Report of two new cases and literature review

SARS‐CoV‐2 vaccination‐induced cutaneous vasculitis: Report of two new cases and literature review

Serious events following COVID‐19 vaccination with ChAdOx1 nCoV‐19 vaccine (Vaxzevria): A short case series from Iran

Leukocytoclastic vasculitis after coronavirus disease 2019 vaccination

Contact Info

Product

Resources

About